MRK

merck-in-talks-to-acquire-revolution-medicines-for-about-$30b-–-wsj

ABBV Biotechnology MRK RVMD Uncategorized

Merck in talks to acquire Revolution Medicines for about $30B – WSJ

Jan 9, 2026

On the Move M&A Comments (18) Marko Georgiev/Getty Images News Merck (MRK) is in talks...

ABBV Biotechnology MRK RVMD Uncategorized

Revolution Medicines soars on report Merck in talks to buy (update)

Jan 8, 2026

ABBV Biotechnology MRK Uncategorized

Merck rises as Wolfe upgrades to Outperform; AbbVie downgraded

Jan 8, 2026

AZN Biotechnology BNTX GCVRZ GSK MRK MRNA NVAX PFE SNY SNYNF Uncategorized

CDC updates childhood vaccine schedule to recommend fewer shots

Jan 5, 2026

Biotechnology EXEL MRK Uncategorized

Exelixis cut to Underperform at BofA on valuation and lack of catalysts

Jan 5, 2026

AZN Biotechnology GILD MRK RPTX Uncategorized

Gilead to buy Repare Thera’s cancer candidate for up to $30M

Dec 24, 2025

abbvie,-bristol-myers,-merck-among-latest-to-announce-us.-drug-pricing-deals:-reuters

ABBV AZN Biotechnology BMY GILD LLY MRK NVO NVS PFE RHHBY Uncategorized

AbbVie, Bristol Myers, Merck among latest to announce U.S. drug pricing deals: Reuters

Dec 19, 2025

Comments (11) LIgorko/iStock via Getty Images Leading drugmakers, including AbbVie (ABBV), Bristol Myers Squibb (BMY),...

Biotechnology MRK PYXS Uncategorized

Pyxis plummets following phase 1 data on candidate for head and neck cancer

Dec 18, 2025

ABBV AMGN AZN Biotechnology BMY GILD GSK JNJ LLY MKGAF MRK NVO NVS PFE REGN SNY Uncategorized

More pharmas expected to sign drug pricing deals with Trump on Friday – report

Dec 17, 2025

adagene,-palvella-gain-after-fda-fast-track-designations

ADAG Biotechnology MRK PVLA Uncategorized

Adagene, Palvella gain after FDA Fast Track Designations

Dec 16, 2025

On the Move Comments JHVEPhoto Adagene (ADAG) and Palvella Therapeutics (PVLA) traded higher in the...

Next Page »